HTR1A and Parkinson disease: Although sarizotan, a phase III 5-HT1A receptor agonist used for the treatment of dyskinesias in Parkinson’s disease (PD) (66, 67) has shown beneficial effects on respiratory dysfunction in different RTT models (34), a phase III clinical trial conducted in 2020 (NCT02790034) has not confirmed these results in a clinical setting.